1) glucocorticoid-induced osteoporosis
糖皮质激素性骨质疏松症
1.
An experimental study on pathogenesis and prevention of glucocorticoid-induced osteoporosis;
糖皮质激素性骨质疏松症的发病机制和预防实验研究
2.
Glucocorticoid-induced osteoporosis is the most frequent secondary osteoporosis, Osteoporotic fractures often result in delayed union and nounion.
糖皮质激素性骨质疏松症是最常见的继发性骨质疏松症,由此引起的病理性骨折常常延迟愈合或不愈合,致残率极高,是骨科领域的一项世界性难题。
2) Glucocorticoid-induced osteoporosis
糖皮质激素性骨质疏松
1.
The association between glucocorticoid-induced osteoporosis and oral health remains a matter of controversy.
随着糖皮质激素在临床上的广泛应用,糖皮质激素性骨质疏松症发病率明显增加。
3) Glucocorticoid induced osteoporosis
糖皮质激素性骨质疏松
1.
Experimental study on therapeutic effects of amylin on glucocorticoid induced osteoporosis in rats;
胰淀素治疗糖皮质激素性骨质疏松大鼠的实验研究
4) Corticosteroid-induced osteoporosis
糖皮质激素引起的骨质疏松
5) Diabetic osteoporosis
糖尿病性骨质疏松症
1.
To study the characteristics of clinical syndromes in diabetic osteoporosis and its early diagnostic and therapeutic methods.
为了解糖尿病性骨质疏松症患者的临床证候特点 ,探讨其早期诊断思路与治法 ,对 42例患者进行临床症状、体征调查及证候辨证 ,结果显示肾虚髓亏、脾气不足、血行不畅在所有患者中均存在 ,为糖尿病性骨质疏松症的主证 ,提示该病的治则应以益肾、健脾、补髓、壮骨、活血相结合 ,临床可以根据其主证及常见症状作出早期诊
2.
To study the clinical effects of QIANGGUBAO(QGB) on diabetic osteoporosis(DOP),the changes of clinical symptoms and bone density in 40 cases before and after being treated with DOP were observed.
为了解强骨宝对糖尿病性骨质疏松症 ( DOP)的临床疗效 ,对 4 0例 DOP患者进行强骨宝颗粒剂用药前后临床症状、骨密度等指标变化的观察。
6) male osteoporosis
男性骨质疏松症
1.
The practice of health education in male osteoporosis using nursing process;
应用护理程序开展男性骨质疏松症健康教育实践
2.
Correlative Research between Male Osteoporosis and Nitrogen Monoxide;
男性骨质疏松症与一氧化氮相关性研究
3.
Male osteoporosis is often overlooked,but male osteoporotic fracture induce more mortality than female osteoporotic fracture,and diagnosis for male osteoporosis has some problems on T scope and value of BMD.
男性骨质疏松症常被忽视,但男性骨质疏松性骨折的死亡率比女性高,且男性诊断骨质疏松症的T值和BMD范围等还存在不同意见。
补充资料：老年性骨质疏松症
老年性骨质疏松症
老年性骨质疏松症又称为Ⅰ型骨质疏松症，发生的年龄为70岁以上，男女性发生比率为1∶2，骨丢失的类型为松质骨和密质骨，处于低骨转换状态，骨丢失速率较缓慢，无骨加速丢失现象，骨折发生部位为椎体(多个楔形)及股骨。老年性骨质疏松发生的原因和年龄老化有关，表现为钙吸收减少，甲状旁腺功能亢进，25-(OH)-D转变为1，25-(OH)2-D3的代谢减低。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条